Oral Argument: Hikma v. Amarin

About this episode

The episode discusses the Supreme Court case Hikma v. Amarin regarding patent infringement and generic drug labeling.

Hikma Pharmaceuticals USA Inc. v. Amarin Pharma, Inc. | Case No. 24-889 | Docket Link: Here Oral Advocates: Petitioners (Hikma): Charles B. Klein of Winston & Strawn LLP Amicus Curiae (United States): Malcolm L. Stewart of the Department of Justice Respondents (Amarin Pharma): Michael R. Huston of Perkins Coie LLP Question Presented: Whether a generic drugmaker that fully carves patented uses from its label actively induces patent infringement through investor press releases and website statements that do not mention, encourage, or instruct the patented use Overview: Generic drugmaker Hikma followed federal skinny-label law but called its product "generic Vascepa" and touted Vascepa's total sales. Brand manufacturer Amarin claims those statements actively induced doctors to prescribe the generic for a patented cardiovascular use worth over $900 million annually. Posture: District court dismissed; Federal Circuit reversed; Supreme Court granted certiorari January 2026. Main Arguments: • Hikma (Petitioner): (1) "Actively" induces requires affirmative steps encouraging infringement — none of Hikma's statements mention or instruct the patented use; (2) Amarin's theory of…

People in this episode

Guests: Charles B. Klein, Malcolm L. Stewart, Michael R. Huston

Topics covered

• patent law
• generic drugs
• pharmaceutical industry
• court cases
• intellectual property

Keywords

• Hikma
• Amarin
• patent infringement
• generic drugs
• skinny-label law
• Supreme Court
• pharmaceuticals

Mentioned in this episode

Organizations: Hikma Pharmaceuticals USA Inc., Amarin Pharma, Inc., Winston & Strawn LLP, Department of Justice, Perkins Coie LLP

More episodes of The High Court Report

• Opinion Summary: Keathley v. Buddy Ayers | Nondisclosure Doesn't Lead to Lawsuit Dismissal · June 12, 2026 · 12 min
• Oral Argument Re-Listen: Hikma Pharmaceuticals v. Amarin Pharma | Generic Drug Beats Patent Trap · June 11, 2026 · 1h 2m
• Opinion Summary: Hikma Pharmaceuticals v. Amarin Pharma | Generic Drug Beats Patent Trap · June 10, 2026 · 1h 2m
• Oral Argument Re-Listen: Sripetch v. SEC | Victimless Fraudsters Can't Keep Profits · June 9, 2026 · 1h 12m
• Opinion Summary: Sripetch v. SEC | Victimless Fraudsters Can't Keep Profits · June 8, 2026 · 15 min
• Oral Argument Re-Listen: FCC v. AT&T | Forfeiture Fines Without Force · June 7, 2026 · 1h 26m